108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months

✍ Scribed by Miller, K.; Smith, M.R.; Dearnaley, D.; Dogliotti, L.; Egerdie, B.; Fizazi, K.; Kueppers, F.; Montes De Oca, L.; Morote, J.; Pavlik, I.; Sieber, P.; Tammela, T.L.; Van Poppel, H.; Wirth, M.; Wong, S.; Ye, Z.; Braun, A.

• Book ID: 123118419
• Publisher: Elsevier Science
• Year: 2013
• Tongue: English
• Weight: 145 KB
• Volume: 12
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/S1569-9056(13)60600-4